ESR1 and breast carcinoma: Interestingly, tamoxifen (TMX) (Figure 5), which is a well-known agonist of estrogenic receptors, currently used for treatment of both early and advanced estrogenic receptor-positive (ER+) breast cancer in pre- and post-menopausal women, also inhibits Kv1.3 channel in human T cells (48).